

the role of the goodpasture antigen binding protein in autoimmunity

Published: 29-12-2010

Last updated: 15-05-2024

Primary Objective: characterization of GPBP expression on different subsets of human leukocytes
Secondary Objective: functional characterization of GPBP on these cells

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Autoimmune disorders
Study type	Observational invasive

Summary

ID

NL-OMON34337

Source

ToetsingOnline

Brief title

GPBP in autoimmunity

Condition

- Autoimmune disorders

Synonym

autoimmunity

Research involving

Human

Sponsors and support

Primary sponsor: Medisch Universitair Ziekenhuis Maastricht

Source(s) of monetary or material Support: Ham Foundation; Prof. Dr. M. De Baets

Intervention

Keyword: autoimmunity, goodpasture antigen binding protein, inflammation, leukocytes

Outcome measures

Primary outcome

Characterization of human leukocyte subsets that express GPBP.

Differences in GPBP expression in different inflammatory conditions (autoimmune vs. healthy)

Secondary outcome

Determination of the function of GPBP on human leukocytes.

Study description

Background summary

The Goodpasture antigen-binding protein (GPBP) is a serine/threonine kinase that binds and phosphorylates collagen type IV, which has a major role in the organisation of the glomerular basement membrane and is the target of autoantibodies mediating glomerulonephritis in Goodpasture syndrome. Several studies have suggested a link between GPBP and the immune system. GPBP has been shown to be upregulated in autoimmune conditions, to transport the signalling lipid ceramide, to be regulated by immune signalling molecules and to interact with pentraxins, the key activators of the complement system. However, the exact role of GPBP in regulation of the (auto)immune response still remains unclear. Therefore, we intend to investigate the exact role of GPBP in the activation and modulation of the immune system.

Study objective

Primary Objective: characterization of GPBP expression on different subsets of human leukocytes

Secondary Objective: functional characterization of GPBP on these cells

Study design

10 ml of venous blood will be obtained from patients with an autoimmune disease or another inflammatory disease. Leukocytes will be isolated from the blood to study GPBP expression and function on these cells. For comparison, it is necessary to study normal, healthy blood cells as well. This will be obtained

from healthy controls.

Study burden and risks

Patients will be asked to give blood during a regular outpatient clinic visit, so it will demand no extra time investment from the patient. For control subject, the most important burden will be time investment. A local bruise is possible on the site of puncture.

Contacts

Public

Medisch Universitair Ziekenhuis Maastricht

Universiteitssingel 50
6229 ER Maastricht
NL

Scientific

Medisch Universitair Ziekenhuis Maastricht

Universiteitssingel 50
6229 ER Maastricht
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Autoimmune patients: 18 - 50 years old, diagnosed with myasthenia gravis or multiple

sclerose

Healthy controls: 18 - 50 years old

Exclusion criteria

no informed consent

minors or incapacitated

healthy controls: previous inflammation related disease

Study design

Design

Study type:	Observational invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Basic science

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	07-02-2011
Enrollment:	100
Type:	Actual

Ethics review

Approved WMO	
Date:	29-12-2010
Application type:	First submission
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 27227

Source: Nationaal Trial Register

Title:

In other registers

Register	ID
CCMO	NL33086.068.10
Other	nog niet gekend
OMON	NL-OMON27227